Project Kent
Submission Date: 24/04/18
Completion Date: 08/03/18
Target: Xstrahl Group
Acquirer: Risk Capital Partners
Deal Value: undisclosed
Deal Description: Charles Russell Speechlys advised on the sale of Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology, to Risk Capital Partners as part of a management buyout. The firm acted for Martin Robinson, the majority shareholder and previous CEO, from whom the business was acquired.
Funding: Private Equity
Corporate Finance Advisers: Lock Dutton Corporate Finance
Legal Advisers: Charles Russell Speechlys
Financial Due Diligence: RSM
Commercial Due Diligence: Mansfield
JTNDJTIxLS0lMjBBZFNwZWVkLmNvbSUyMFRhZyUyMDguMC4yJTIwZm9yJTIwJTVCWm9uZSU1RCUyMERlYWxzJTIwdXBkYXRlJTIwYWR2ZXJ0JTIwZm9yJTIwQnVzbWFnJTIwJTVCQW55JTIwRGltZW5zaW9uJTVEJTIwLS0lM0UlMEElM0NzY3JpcHQlMjB0eXBlJTNEJTIydGV4dCUyRmphdmFzY3JpcHQlMjIlMjBzcmMlM0QlMjJodHRwcyUzQSUyRiUyRmcuYWRzcGVlZC5uZXQlMkZhZC5waHAlM0ZkbyUzRGpzJTI2emlkJTNEODkzNTclMjZvaWQlM0QxMjA4MyUyNndkJTNELTElMjZodCUzRC0xJTI2dGFyZ2V0JTNEX2JsYW5rJTIyJTNFJTNDJTJGc2NyaXB0JTNFJTBBJTNDJTIxLS0lMjBBZFNwZWVkLmNvbSUyMEVuZCUyMC0tJTNF
